vs
Medpace Holdings, Inc.（MEDP）与NATIONAL RESEARCH CORP（NRC）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是NATIONAL RESEARCH CORP的20.1倍（$708.5M vs $35.2M）。Medpace Holdings, Inc.净利率更高（19.1% vs 5.1%，领先14.0%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -4.6%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $6.1M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -0.2%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
MEDP vs NRC — 直观对比
营收规模更大
MEDP
是对方的20.1倍
$35.2M
营收增速更快
MEDP
高出36.7%
-4.6%
净利率更高
MEDP
高出14.0%
5.1%
自由现金流更多
MEDP
多$182.1M
$6.1M
两年增速更快
MEDP
近两年复合增速
-0.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $35.2M |
| 净利润 | $135.1M | $1.8M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | 13.3% |
| 净利率 | 19.1% | 5.1% |
| 营收同比 | 32.0% | -4.6% |
| 净利润同比 | 15.5% | -72.6% |
| 每股收益（稀释后） | $4.65 | $49.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPNRC
| Q4 25 | $708.5M | $35.2M | ||
| Q3 25 | $659.9M | $34.6M | ||
| Q2 25 | $603.3M | $34.0M | ||
| Q1 25 | $558.6M | $33.6M | ||
| Q4 24 | $536.6M | $36.9M | ||
| Q3 24 | $533.3M | $35.8M | ||
| Q2 24 | $528.1M | $35.0M | ||
| Q1 24 | $511.0M | $35.3M |
净利润MEDPNRC
| Q4 25 | $135.1M | $1.8M | ||
| Q3 25 | $111.1M | $4.1M | ||
| Q2 25 | $90.3M | $-106.0K | ||
| Q1 25 | $114.6M | $5.8M | ||
| Q4 24 | $117.0M | $6.6M | ||
| Q3 24 | $96.4M | $5.7M | ||
| Q2 24 | $88.4M | $6.2M | ||
| Q1 24 | $102.6M | $6.4M |
营业利润率MEDPNRC
| Q4 25 | 21.6% | 13.3% | ||
| Q3 25 | 21.5% | 22.4% | ||
| Q2 25 | 20.9% | 4.7% | ||
| Q1 25 | 20.3% | 25.6% | ||
| Q4 24 | 23.4% | 26.0% | ||
| Q3 24 | 21.1% | 22.3% | ||
| Q2 24 | 19.9% | 25.3% | ||
| Q1 24 | 20.4% | 24.8% |
净利率MEDPNRC
| Q4 25 | 19.1% | 5.1% | ||
| Q3 25 | 16.8% | 11.9% | ||
| Q2 25 | 15.0% | -0.3% | ||
| Q1 25 | 20.5% | 17.2% | ||
| Q4 24 | 21.8% | 17.8% | ||
| Q3 24 | 18.1% | 15.9% | ||
| Q2 24 | 16.7% | 17.6% | ||
| Q1 24 | 20.1% | 18.0% |
每股收益（稀释后）MEDPNRC
| Q4 25 | $4.65 | $49.58 | ||
| Q3 25 | $3.86 | $0.18 | ||
| Q2 25 | $3.10 | $-0.01 | ||
| Q1 25 | $3.67 | $0.25 | ||
| Q4 24 | $3.67 | $0.27 | ||
| Q3 24 | $3.01 | $0.24 | ||
| Q2 24 | $2.75 | $0.26 | ||
| Q1 24 | $3.20 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $4.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $14.0M |
| 总资产 | $2.0B | $134.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPNRC
| Q4 25 | $497.0M | $4.1M | ||
| Q3 25 | $285.4M | $2.2M | ||
| Q2 25 | $46.3M | $5.3M | ||
| Q1 25 | $441.4M | $2.5M | ||
| Q4 24 | $669.4M | $4.2M | ||
| Q3 24 | $656.9M | $3.5M | ||
| Q2 24 | $510.9M | $485.0K | ||
| Q1 24 | $407.0M | $1.7M |
总债务MEDPNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $48.7M | ||
| Q2 24 | — | $33.3M | ||
| Q1 24 | — | $35.2M |
股东权益MEDPNRC
| Q4 25 | $459.1M | $14.0M | ||
| Q3 25 | $293.6M | $14.3M | ||
| Q2 25 | $172.4M | $21.3M | ||
| Q1 25 | $593.6M | $29.7M | ||
| Q4 24 | $825.5M | $31.3M | ||
| Q3 24 | $881.4M | $34.6M | ||
| Q2 24 | $763.6M | $40.2M | ||
| Q1 24 | $671.5M | $36.9M |
总资产MEDPNRC
| Q4 25 | $2.0B | $134.9M | ||
| Q3 25 | $1.8B | $135.7M | ||
| Q2 25 | $1.6B | $141.4M | ||
| Q1 25 | $1.9B | $135.2M | ||
| Q4 24 | $2.1B | $132.5M | ||
| Q3 24 | $2.1B | $131.8M | ||
| Q2 24 | $1.9B | $119.1M | ||
| Q1 24 | $1.8B | $120.9M |
负债/权益比MEDPNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 0.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $6.1M |
| 自由现金流率自由现金流/营收 | 26.6% | 17.2% |
| 资本支出强度资本支出/营收 | 0.6% | 3.2% |
| 现金转化率经营现金流/净利润 | 1.43× | 3.99× |
| 过去12个月自由现金流最近4个季度 | $681.9M | $15.7M |
8季度趋势，按日历期对齐
经营现金流MEDPNRC
| Q4 25 | $192.7M | $7.2M | ||
| Q3 25 | $246.2M | $13.8M | ||
| Q2 25 | $148.5M | $-1.1M | ||
| Q1 25 | $125.8M | $6.6M | ||
| Q4 24 | $190.7M | $6.4M | ||
| Q3 24 | $149.1M | $9.4M | ||
| Q2 24 | $116.4M | $6.8M | ||
| Q1 24 | $152.7M | $12.0M |
自由现金流MEDPNRC
| Q4 25 | $188.1M | $6.1M | ||
| Q3 25 | $235.5M | $10.2M | ||
| Q2 25 | $142.4M | $-4.1M | ||
| Q1 25 | $115.8M | $3.7M | ||
| Q4 24 | $183.0M | $1.9M | ||
| Q3 24 | $138.5M | $7.8M | ||
| Q2 24 | $103.5M | $1.5M | ||
| Q1 24 | $147.2M | $7.9M |
自由现金流率MEDPNRC
| Q4 25 | 26.6% | 17.2% | ||
| Q3 25 | 35.7% | 29.4% | ||
| Q2 25 | 23.6% | -12.2% | ||
| Q1 25 | 20.7% | 10.9% | ||
| Q4 24 | 34.1% | 5.2% | ||
| Q3 24 | 26.0% | 21.8% | ||
| Q2 24 | 19.6% | 4.3% | ||
| Q1 24 | 28.8% | 22.4% |
资本支出强度MEDPNRC
| Q4 25 | 0.6% | 3.2% | ||
| Q3 25 | 1.6% | 10.4% | ||
| Q2 25 | 1.0% | 8.8% | ||
| Q1 25 | 1.8% | 8.9% | ||
| Q4 24 | 1.4% | 12.0% | ||
| Q3 24 | 2.0% | 4.5% | ||
| Q2 24 | 2.4% | 15.0% | ||
| Q1 24 | 1.1% | 11.7% |
现金转化率MEDPNRC
| Q4 25 | 1.43× | 3.99× | ||
| Q3 25 | 2.22× | 3.34× | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | 1.15× | ||
| Q4 24 | 1.63× | 0.97× | ||
| Q3 24 | 1.55× | 1.66× | ||
| Q2 24 | 1.32× | 1.10× | ||
| Q1 24 | 1.49× | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
NRC
暂无分部数据
